AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy

Sergia Bortolanza, Alessandro Nonis, Francesca Sanvito, Simona MacIotta, Giovanni Sitia, Jessica Wei, Yvan Torrente, Clelia Di Serio, Joel R. Chamberlain, Davide Gabellini

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Treatment of dominantly inherited muscle disorders remains a difficult task considering the need to eliminate the pathogenic gene product in a body-wide fashion. We show here that it is possible to reverse dominant muscle disease in a mouse model of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a common form of muscular dystrophy associated with a complex cascade of epigenetic events following reduction in copy number of D4Z4 macrosatellite repeats located on chromosome 4q35. Several 4q35 genes have been examined for their role in disease, including FRG1. Overexpression of FRG1 causes features related to FSHD in transgenic mice and the FRG1 mouse is currently the only available mouse model of FSHD. Here we show that systemic delivery of RNA interference expression cassettes in the FRG1 mouse, after the onset of disease, led to a dose-dependent long-term FRG1 knockdown without signs of toxicity. Histological features including centrally nucleated fibers, fiber size reduction, fibrosis, adipocyte accumulation, and inflammation were all significantly improved. FRG1 mRNA knockdown resulted in a dramatic restoration of muscle function. Through RNA interference (RNAi) expression cassette redesign, our method is amenable to targeting any pathogenic gene offering a viable option for long-term, body-wide treatment of dominant muscle disease in humans.

Original languageEnglish
Pages (from-to)2055-2064
Number of pages10
JournalMolecular Therapy
Volume19
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Facioscapulohumeral Muscular Dystrophy
Small Interfering RNA
RNA Interference
Muscles
Genes
Muscular Dystrophies
Muscular Diseases
Adipocytes
Epigenomics
Transgenic Mice
Fibrosis
Chromosomes
Inflammation
Messenger RNA

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. / Bortolanza, Sergia; Nonis, Alessandro; Sanvito, Francesca; MacIotta, Simona; Sitia, Giovanni; Wei, Jessica; Torrente, Yvan; Di Serio, Clelia; Chamberlain, Joel R.; Gabellini, Davide.

In: Molecular Therapy, Vol. 19, No. 11, 11.2011, p. 2055-2064.

Research output: Contribution to journalArticle

@article{b5fa09355d5b46519417db6be774b9a1,
title = "AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy",
abstract = "Treatment of dominantly inherited muscle disorders remains a difficult task considering the need to eliminate the pathogenic gene product in a body-wide fashion. We show here that it is possible to reverse dominant muscle disease in a mouse model of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a common form of muscular dystrophy associated with a complex cascade of epigenetic events following reduction in copy number of D4Z4 macrosatellite repeats located on chromosome 4q35. Several 4q35 genes have been examined for their role in disease, including FRG1. Overexpression of FRG1 causes features related to FSHD in transgenic mice and the FRG1 mouse is currently the only available mouse model of FSHD. Here we show that systemic delivery of RNA interference expression cassettes in the FRG1 mouse, after the onset of disease, led to a dose-dependent long-term FRG1 knockdown without signs of toxicity. Histological features including centrally nucleated fibers, fiber size reduction, fibrosis, adipocyte accumulation, and inflammation were all significantly improved. FRG1 mRNA knockdown resulted in a dramatic restoration of muscle function. Through RNA interference (RNAi) expression cassette redesign, our method is amenable to targeting any pathogenic gene offering a viable option for long-term, body-wide treatment of dominant muscle disease in humans.",
author = "Sergia Bortolanza and Alessandro Nonis and Francesca Sanvito and Simona MacIotta and Giovanni Sitia and Jessica Wei and Yvan Torrente and {Di Serio}, Clelia and Chamberlain, {Joel R.} and Davide Gabellini",
year = "2011",
month = "11",
doi = "10.1038/mt.2011.153",
language = "English",
volume = "19",
pages = "2055--2064",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy

AU - Bortolanza, Sergia

AU - Nonis, Alessandro

AU - Sanvito, Francesca

AU - MacIotta, Simona

AU - Sitia, Giovanni

AU - Wei, Jessica

AU - Torrente, Yvan

AU - Di Serio, Clelia

AU - Chamberlain, Joel R.

AU - Gabellini, Davide

PY - 2011/11

Y1 - 2011/11

N2 - Treatment of dominantly inherited muscle disorders remains a difficult task considering the need to eliminate the pathogenic gene product in a body-wide fashion. We show here that it is possible to reverse dominant muscle disease in a mouse model of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a common form of muscular dystrophy associated with a complex cascade of epigenetic events following reduction in copy number of D4Z4 macrosatellite repeats located on chromosome 4q35. Several 4q35 genes have been examined for their role in disease, including FRG1. Overexpression of FRG1 causes features related to FSHD in transgenic mice and the FRG1 mouse is currently the only available mouse model of FSHD. Here we show that systemic delivery of RNA interference expression cassettes in the FRG1 mouse, after the onset of disease, led to a dose-dependent long-term FRG1 knockdown without signs of toxicity. Histological features including centrally nucleated fibers, fiber size reduction, fibrosis, adipocyte accumulation, and inflammation were all significantly improved. FRG1 mRNA knockdown resulted in a dramatic restoration of muscle function. Through RNA interference (RNAi) expression cassette redesign, our method is amenable to targeting any pathogenic gene offering a viable option for long-term, body-wide treatment of dominant muscle disease in humans.

AB - Treatment of dominantly inherited muscle disorders remains a difficult task considering the need to eliminate the pathogenic gene product in a body-wide fashion. We show here that it is possible to reverse dominant muscle disease in a mouse model of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a common form of muscular dystrophy associated with a complex cascade of epigenetic events following reduction in copy number of D4Z4 macrosatellite repeats located on chromosome 4q35. Several 4q35 genes have been examined for their role in disease, including FRG1. Overexpression of FRG1 causes features related to FSHD in transgenic mice and the FRG1 mouse is currently the only available mouse model of FSHD. Here we show that systemic delivery of RNA interference expression cassettes in the FRG1 mouse, after the onset of disease, led to a dose-dependent long-term FRG1 knockdown without signs of toxicity. Histological features including centrally nucleated fibers, fiber size reduction, fibrosis, adipocyte accumulation, and inflammation were all significantly improved. FRG1 mRNA knockdown resulted in a dramatic restoration of muscle function. Through RNA interference (RNAi) expression cassette redesign, our method is amenable to targeting any pathogenic gene offering a viable option for long-term, body-wide treatment of dominant muscle disease in humans.

UR - http://www.scopus.com/inward/record.url?scp=80455173941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455173941&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.153

DO - 10.1038/mt.2011.153

M3 - Article

C2 - 21829175

AN - SCOPUS:80455173941

VL - 19

SP - 2055

EP - 2064

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 11

ER -